One particularly attractive avenue for this drug-targeting paradigm has been the use of radiolabeled synthetic peptide analogs of α-melanocyte stimulating hormone (α-MSH) to deliver radionuclides to the melanoma tumor microenvironment via binding with MC1R. This evidence concerns the gene MC1R and neoplasm.